Clinical Trial Update: Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating fulvestrant with or without anastrozole versus exemestane after progression on non-steroidal aromatase inhibitors has completed, with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ARIMIDEX (anastrozole)
• Exemestane (Exemestane)
• Faslodex (fulvestrant)

Snippet

Sponsor: AstraZeneca | Conditions: Progression-free Survival | Phase 3 | Status: COMPLETED